Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Ep... (l(R) 40 -7.0% 26 ...)

Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin

Date:4/30/2008

l(R) 40 -7.0% 26 +18.2% 17 +21.4%

Actonel(R) 48 -4.0% - - 27 +3.8%

Nasacort(R) 11 -15.4% 52 -1.9% 7 +16.7%

Comments by product

Lovenox(R), the leading low molecular weight heparin on the market, continued to benefit from the extension of its use in medical prophylaxis in the United States. Net sales of the product were sharply up in the period by 21.5%, at EURO 717 million, with strong performances in all three geographic regions.

Lovenox(R) was approved in January in Japan and launched in April. The product is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing orthopedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery.

Net sales of Lantus(R), the world's leading insulin brand, rose by 30.8% in the quarter to EURO 557 million. In the United States, net sales advanced by 35.7% to EURO 327 million. Sales growth is supported by the new disposable pen, LantusSoloSTAR(R).

Taxotere(R) recorded similar growth in all three geographic regions. In the United States, sales growth was higher than in previous periods at 14.0% due to strong demand for the product as an adjuvant breast cancer treatment.

Ambien CR(R) posted net sales of EURO 123 million in the United States. Net sales of Ambien(R) IR, which went off patent in the United States on April 20, 2007, totaled EURO 26 million in Q1 2008 versus EURO 363 million for the comparable period of 2007.

In Japan, sales of Myslee(R), which have been consolidated by sanofi-aventis since January 1, 2008, were up 8.5% at EURO 25 million.

In the United States, Eloxatin(R), the market-leading colorectal cancer treatment as adjuvant and in the metastatic phase, recorded first-quarter net sales growth of 5.0% to EURO 230 million. Total net sales of Eloxatin(R) were down 6.0%
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Tubbs Jones Introduces Resolution Encouraging STD Prevention
2. New electronic health records demonstration project encouraging step says ACP
3. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
4. Digirad Corporation Reports Financial Results for First-Quarter 2008
5. Essilors 2008 First-Quarter Report
6. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
9. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Abbott Hosts Conference Call for First-Quarter Earnings

Post Your Comments:

Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Ep...(l(R) 40 -7.0% 26 ...),Health